• A Gossmann, T H Helbich, S Mesiano, D M Shames, M F Wendland, T P Roberts, N Ferrara, R B Jaffe, and R C Brasch.
• Center for Pharmaceutical and Molecular Imaging, Department of Radiology, University of California San Francisco, San Francisco, CA 94143-0628, USA.
• Am. J. Obstet. Gynecol. 2000 Oct 1; 183 (4): 956-63.

ObjectiveMagnetic resonance imaging enhanced with macromolecular contrast medium was used to monitor effects of angiogenesis inhibition on tumor microvascular permeability and ascites volume in an athymic rat model of human ovarian cancer.Study DesignGroups of 6 athymic rats implanted intraperitoneally with SKOV-3, a human ovarian cancer cell line, were treated through a 14-day course with antibody to vascular endothelial growth factor or with saline solution for control animals. Dynamic magnetic resonance imaging was performed with a 92,000-d contrast agent, albumin-(gadolinium-diethylenetriaminepentaacetic acid)(30). Vascular permeability was estimated from dynamic enhancement data that were analyzed with a unidirectional 2-compartment kinetic model.ResultsAnimals treated with vascular endothelial growth factor antibody accumulated significantly smaller volumes of peritoneal ascites (P <.05) and showed significantly lower magnetic resonance imaging-assayed tumor microvascular permeabilities (P <.05) than did control animals.ConclusionMagnetic resonance imaging enhanced with a macromolecular contrast agent in an athymic rat model of human ovarian cancer treated with anti-vascular endothelial growth factor antibody can be used to measure a reduction in tumor microvascular permeability, corresponding to a reduction in ascites production.

26 keywords...

hide…